This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Amgen’s leukemia drug Blincyto received full approval from the U.S. Food and Drug Administration on July 11 to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia in adults and children. The biotech giant, headquartered in Thousand Oaks, had previously announced that the drug had been fast-tracked for priority review. The full approval includes data Read More →
Thousand Oaks-based biotech giant Amgen announced March 29 that the U.S. Food and Drug Administration has fast-tracked the company’s leukemia drug Blincyto for priority review. The drug increases the length of survival among high-risk patients, according to a study released by the New England Journal of Medicine. It almost doubled median overall survival versus chemotherapy among adult patients Read More →
Amgen’s new leukemia drug cured 39 percent of pediatric patients who received treatment, the Thousand Oaks company said Oct. 3 after publishing results of a new study in the Journal of Clinical Oncology. Blincyto, which treats a rare form of the disease known as precursor B-cell acute lymphoblastic leukemia, sent 27 patients out of 70 Read More →
The U.S. Food and Drug Administration approved Amgen’s drug Blincyto for treating pediatric leukemia patients Sept. 1. In Dec. 2014, the FDA approved Blincyto to treat patients with precursor B-cell acute lymphoblastic leukemia, which is a rare form of the disease. On Sept. 1, the agency extended Blincyto’s approval to include pediatric patients with another Read More →